miRagen Therapeutics and The Leukemia & Lymphoma Society announced that they entered into an agreement providing for collaboration and funding intended to support the development of miRagen’s cobomarsen, a microRNA-155 inhibitor, for the treatment of patients with the mycosis fungoides form of cutaneous T-cell lymphoma. There are approximately 16,000-20,000 people in the U.S. with mycosis fungoides. LLS will provide up to $5M through the purchase of miRagen common stock to help support the SOLAR trial. This includes a $1M investment upon signing of the agreement and potential additional stock purchases upon the achievement of certain milestones during the SOLAR trial. Funding from LLS is being provided under its Therapy Acceleration Program, a strategic initiative through which LLS partners directly with biotechnology companies and academic institutions to help accelerate the development of promising therapies. Additionally, LLS will continue to provide comprehensive patient support and education to MF patients to help them better understand their treatment options. Through LLS’s Clinical Trial Support Center, specially trained nurses will help MF patients find and enroll in clinical trials based on highly detailed, individualized assessments.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.